Search alternatives:
point decrease » point increase (Expand Search)
ex decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
i ex » i e (Expand Search), i x (Expand Search)
point decrease » point increase (Expand Search)
ex decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
i ex » i e (Expand Search), i x (Expand Search)
-
961
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
Published 2025Subjects: -
962
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
Published 2025Subjects: -
963
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
Published 2025Subjects: -
964
-
965
-
966
Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.
Published 2025Subjects: -
967
Baseline patient characteristics across neutralizing monoclonal antibody trials.
Published 2025Subjects: -
968
-
969
-
970
-
971
-
972
-
973
-
974
-
975
-
976
-
977
-
978
-
979
-
980